Results from lantanoprostene bunod clinical studies presented at ARVO

May 15, 2014

The results of 2 clinical studies on latanosprostene bunod-CONSTELLATION and KRONUS- were presented during the Association for Research in Vision and Ophthalmology meeting last week.

Orlando, FL-The results of 2 clinical studies on latanosprostene bunod-CONSTELLATION and KRONUS- were presented during the Association for Research in Vision and Ophthalmology meeting last week. 

Dr. John H Liu gave a presentation titled “Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Lowering IOP over 24 hours in Subjects With Open Angle Glaucoma or Ocular Hypertension (CONSTELLATION),” on the results from CONSTELLATION, a cross-over Phase 2 study. According to Nicox, the objective “was to compare the effect of latanoprostene bunod 0.024% QD with timolol maleate 0.5% BID in reducing 24-hour intraocular pressure (IOP) in subjects with open angle glaucoma or ocular hypertension.”

According to the study’s abstract, the results showed that “this group of open angle glaucoma/ocular hypertensive patients, LBN 0.024% was shown to be superior to timolol with regard to IOP lowering during the entire 24 hour period measured (p<0.05), suggesting that treatment with LBN 0.024% may provide more effective and better sustained diurnal and nocturnal IOP reduction.”

The Phase 1 results from KRONUS, a Japanese clinical trial which aimed to “evaluate the effect of latanoprostene bunod 0.024% QD on diurnal IOP over a 24-hour period in healthy Japanese subjects following 14 days of treatment,” were presented in a poster titled, “Efficacy of Latanoprostene Bunod Ophthalmic Solution, 0.024%, in Lowering Intraocular Pressure Over 24-Hours in Normal Japanese Subjects (KRONUS).”

According to the study’s abstract, “Latanoprostene bunod, 0.024% dosed QD for 14 days significantly lowered IOP in normal Japanese subjects during the entire 24 hour period from 13.6 to 10.0 mmHg, corresponding to 27% reduction in mean 24-hour IOP. The current result suggests potential of this compound in providing sustained 24-hour IOP reduction to glaucoma patients not only with elevated, but also with normal IOP.”